Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Shares climbed in pre-market and overnight trading as investors positioned for topline results from the 36-week induction period of Nektar’s Phase 2b REZOLVE-AA study in severe-to-very-severe alopecia areata, featuring its lead investigational candidate rezpegaldesleukin. The company scheduled an investor call and webcast for 8:00 a.m. ET, and said the topline results would be released in a morning press release before the webcast. PR Newswire+1